{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/selank",
  "canonicalUrl": "https://thepeptidefield.com/peptides/selank",
  "record": {
    "slug": "selank",
    "name": "Selank",
    "aliases": [
      "TP-7",
      "Selanc"
    ],
    "className": "Synthetic neuropeptide",
    "family": "Synthetic neuropeptides",
    "sequenceLabel": "7 amino acids · Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)",
    "tier": "Emerging",
    "evidenceContext": "Investigational human outcomes",
    "statusLine": "No FDA-approved U.S. Selank product was found in the records checked on August 30, 2026",
    "productContext": "FDA has separate records for Selank and Selank diacetate, a related chemical form. FDA's compounding page uses the name Selank acetate. These records do not show that a sold or compounded product contains the listed form or matches the product used in a study.",
    "approvedProducts": [],
    "productRecords": [],
    "indications": [
      "Small human studies of anxiety-related conditions",
      "A human brain-scan study"
    ],
    "profile": {
      "humanOutcomes": {
        "level": "Limited",
        "note": "Small studies compared Selank with anxiety medicines. They reported symptom changes. The records reviewed did not include a large repeat study against a placebo."
      },
      "humanPharmacology": {
        "level": "Limited",
        "note": "A 52-person study measured changes in links between brain areas. It did not measure a treatment benefit, focus, memory, or daily function."
      },
      "safetyKnowledge": {
        "level": "Limited",
        "note": "Small studies cannot show uncommon or long-term harms. FDA says important human safety information is missing for the Selank acetate form."
      },
      "productCertainty": {
        "level": "Unclear",
        "note": "The main peptide, a related chemical form, the product used in a study, and products sold as Selank are not automatically the same."
      }
    },
    "oneLine": "Selank is a seven-amino-acid peptide. Small studies in people do not prove that it treats anxiety or improves focus.",
    "reviewedAt": "August 30, 2026",
    "reviewedAtISO": "2026-08-30",
    "reviewHistory": [
      {
        "date": "2026-08-30",
        "note": "Initial brief reviewed FDA identity, approval, and compounding records, three small anxiety studies, and a human brain-scan study."
      }
    ],
    "whatItIs": "Selank is a peptide with seven amino acids. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, also written as TKPRPGP. FDA also lists the names TP-7 and Selanc for this peptide. Selank diacetate is a related chemical form, not another name for every Selank product.",
    "whatWeKnow": "One study compared Selank with medazepam in 62 people. A second study compared Selank with phenazepam in 60 people with several anxiety-related conditions. Both reported symptom improvement. Neither cited study summary describes a placebo group, and both summaries gave few details about the methods.\n\nA separate study used brain scans in 52 healthy people who received Selank, Semax, or placebo. It found changes in links between some brain areas. It did not test anxiety treatment, focus, memory, or daily function.",
    "whatWeDoNotKnow": "These small studies do not show that Selank is a proven anxiety treatment. They also do not prove better focus, memory, sleep, mood, or daily function. Most reports came from Russian research groups. The reports gave few details about whether people or researchers knew the assigned treatment. They also gave little information about longer follow-up or uncommon harms. No large, independent repeat study was found among the records reviewed.\n\nNo FDA-approved U.S. Selank drug was found. FDA says important human safety information is missing for the Selank acetate form. The reviewed records do not show whether an online or compounded product contains the listed chemical form or matches the product used in a study.",
    "antiDoping": null,
    "safetyBoundary": "FDA warns of possible immune reactions with some ways of using compounded Selank acetate. Peptide clumps or related impurities could cause the reaction. FDA also says important human safety information is missing for this chemical form. Short studies cannot show uncommon or long-term harms. This guide gives no dosing, spray, injection, buying, sourcing, or treatment advice.",
    "relatedSlugs": [
      "semax",
      "dsip",
      "cerebrolysin"
    ],
    "claims": [
      {
        "claim": "“Selank, Selanc, and TP-7 are names for the same seven-amino-acid peptide.”",
        "verdict": "Supported with scope",
        "explanation": "Yes. FDA lists Selank, Selanc, and TP-7 as names for one peptide with the sequence TKPRPGP. This record names the substance. It does not show that a related chemical form or sold product is the same.",
        "category": "Mechanism and biomarkers",
        "evidenceBasis": "Regulatory or product record",
        "scope": "The Selank peptide in FDA's chemical record. Selank diacetate has a separate related record.",
        "sourceUrls": [
          "https://precision.fda.gov/uniisearch/srs/unii/TS9JR8EP1G",
          "https://precision.fda.gov/ginas/app/ui/substances/TS9JR8EP1G"
        ]
      },
      {
        "claim": "“Small studies tested Selank in people with anxiety-related conditions.”",
        "verdict": "Supported with scope",
        "explanation": "Yes. One randomized report compared Selank with medazepam in 62 people. Another randomized report included 70 people. Forty received Selank with phenazepam, and 30 received phenazepam alone. These small studies do not prove a broad benefit.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Randomized human outcomes",
        "scope": "Small studies in people with specific anxiety-related conditions. The reports do not establish a result for every anxiety condition or population.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/18454096/",
          "https://pubmed.ncbi.nlm.nih.gov/26356395/"
        ]
      },
      {
        "claim": "“Selank is a proven treatment for anxiety.”",
        "verdict": "Not established",
        "explanation": "The studies were small and compared Selank with another medicine. The reports did not clearly say whether people and researchers knew the assigned treatment. No large, repeated result against a placebo was found.",
        "category": "Clinical outcomes",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "A reliable treatment conclusion for anxiety disorders across people, settings, and products.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/18454096/",
          "https://pubmed.ncbi.nlm.nih.gov/25176261/",
          "https://pubmed.ncbi.nlm.nih.gov/26356395/"
        ]
      },
      {
        "claim": "“Selank improves focus, memory, or daily function.”",
        "verdict": "Not established",
        "explanation": "A 52-person study measured links between brain areas. It did not test focus, memory, or daily function. An earlier report mentioned a possible effect on thinking, but its study summary gave no clear result for these outcomes.",
        "category": "Clinical outcomes",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "Focus, memory, and daily-function outcomes in people who received a verified Selank study product.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/32342318/",
          "https://pubmed.ncbi.nlm.nih.gov/25176261/"
        ]
      },
      {
        "claim": "“Selank is FDA-approved in the United States.”",
        "verdict": "Misleading",
        "explanation": "No FDA-approved U.S. Selank product was found in the records checked. FDA's chemical record names the substance. It does not approve a drug. The request to add Selank acetate to a compounding list was withdrawn. That request was not approval.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "United States drug-approval and compounding records checked on August 30, 2026.",
        "sourceUrls": [
          "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
          "https://precision.fda.gov/uniisearch/srs/unii/TS9JR8EP1G",
          "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"
        ]
      },
      {
        "claim": "“Selank, Selank diacetate, and every product sold as Selank are interchangeable.”",
        "verdict": "Misleading",
        "explanation": "FDA has separate records for the main peptide and Selank diacetate, a related chemical form. A product name does not prove what it contains, its quality, or whether it matches the product used in a study.",
        "category": "Product equivalence",
        "evidenceBasis": "Regulatory or product record",
        "scope": "The peptide, its related chemical form, and each finished or compounded product must be checked separately.",
        "sourceUrls": [
          "https://precision.fda.gov/ginas/app/ui/substances/TS9JR8EP1G",
          "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"
        ]
      },
      {
        "claim": "“Selank has a proven safety profile in people.”",
        "verdict": "Not established",
        "explanation": "The human studies were small and cannot show uncommon or long-term harms. FDA says important human safety information is missing for Selank acetate. For some ways of using it, FDA also warns of possible immune reactions from peptide clumps or related impurities.",
        "category": "Safety",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "Long-term safety, uncommon harms, and the safety of each way it is used, chemical form, and finished product.",
        "sourceUrls": [
          "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
          "https://pubmed.ncbi.nlm.nih.gov/18454096/",
          "https://pubmed.ncbi.nlm.nih.gov/25176261/"
        ]
      }
    ],
    "sources": [
      {
        "label": "FDA substance record for Selank, Selanc, and TP-7",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://precision.fda.gov/uniisearch/srs/unii/TS9JR8EP1G",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "FDA current substance record showing the related Selank diacetate form",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://precision.fda.gov/ginas/app/ui/substances/TS9JR8EP1G",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Selank compared with medazepam in 62 people",
        "publisher": "PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova",
        "url": "https://pubmed.ncbi.nlm.nih.gov/18454096/",
        "kind": "Randomized trial",
        "year": 2008,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Selank compared with phenazepam in 60 people",
        "publisher": "PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova",
        "url": "https://pubmed.ncbi.nlm.nih.gov/25176261/",
        "kind": "Human clinical study",
        "year": 2014,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Phenazepam alone compared with phenazepam plus Selank in 70 people",
        "publisher": "PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova",
        "url": "https://pubmed.ncbi.nlm.nih.gov/26356395/",
        "kind": "Randomized trial",
        "year": 2015,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Selank, Semax, and placebo brain-scan study in 52 healthy people",
        "publisher": "PubMed · Doklady Biological Sciences",
        "url": "https://pubmed.ncbi.nlm.nih.gov/32342318/",
        "kind": "Human pharmacology",
        "year": 2020,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "FDA list of withdrawn compounding requests and safety concerns",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Drugs@FDA approved-drug search",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      }
    ],
    "antiDopingReview": {
      "status": "Not assessed",
      "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.",
      "sourceUrl": null,
      "reviewedAtISO": "2026-08-30"
    }
  }
}